Abstract
Design and syntheses of a novel series of muscarinic antagonists are reported. These efforts have culminated in the discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide (4a) as a potent and pan-active muscarinic antagonist as well as a functionally active compound in a murine model of bronchoconstriction. The compound has also displayed pharmacokinetic characteristics suitable for inhaled delivery.
MeSH terms
-
Administration, Inhalation
-
Animals
-
Biphenyl Compounds / chemical synthesis
-
Biphenyl Compounds / chemistry*
-
Biphenyl Compounds / pharmacokinetics
-
Bridged Bicyclo Compounds, Heterocyclic / chemical synthesis
-
Bridged Bicyclo Compounds, Heterocyclic / chemistry*
-
Bridged Bicyclo Compounds, Heterocyclic / pharmacokinetics
-
Drug Discovery
-
Humans
-
Mice
-
Muscarinic Antagonists / chemical synthesis
-
Muscarinic Antagonists / chemistry*
-
Muscarinic Antagonists / pharmacokinetics
-
Pulmonary Disease, Chronic Obstructive / drug therapy*
-
Rats
-
Receptors, Muscarinic / chemistry*
-
Receptors, Muscarinic / metabolism
-
Structure-Activity Relationship
Substances
-
(3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo( 3.2.1)octane bromide
-
Biphenyl Compounds
-
Bridged Bicyclo Compounds, Heterocyclic
-
Muscarinic Antagonists
-
Receptors, Muscarinic